BRINK
发表于 2025-3-23 09:53:48
http://reply.papertrans.cn/19/1877/187667/187667_11.png
ARENA
发表于 2025-3-23 14:58:28
http://reply.papertrans.cn/19/1877/187667/187667_12.png
分开如此和谐
发表于 2025-3-23 21:03:25
http://reply.papertrans.cn/19/1877/187667/187667_13.png
Tractable
发表于 2025-3-24 02:05:07
Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment Practices,ery year although the incidence appears increased in patients originating from Latin America (Douer in Best Pract Res Clin Haematol 16:357–367, 2003). Notably, the median age at diagnosis is approximately 40 years which is significantly lower than in AML where the median age is 68 years.
厌倦吗你
发表于 2025-3-24 05:40:44
http://reply.papertrans.cn/19/1877/187667/187667_15.png
无法解释
发表于 2025-3-24 08:04:04
http://reply.papertrans.cn/19/1877/187667/187667_16.png
安心地散步
发表于 2025-3-24 14:11:34
http://reply.papertrans.cn/19/1877/187667/187667_17.png
Lasting
发表于 2025-3-24 17:17:38
http://reply.papertrans.cn/19/1877/187667/187667_18.png
machination
发表于 2025-3-24 20:41:55
Die wichtigsten Kommunikationsmodelleluding those with . deletions/mutations who previously had a dismal outcome with conventional chemoimmunotherapy. Allogeneic HCT is a potentially curative option for selected younger patients with multiply relapsed high-risk disease.
Watemelon
发表于 2025-3-25 02:42:06
Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma,hniques to detect this entity are complex and are not widely available. This chapter discusses various subsets of ALL and describes our approach to the accurate classification and prognostication of these cases.